0000899243-21-035417.txt : 20210909
0000899243-21-035417.hdr.sgml : 20210909
20210909161518
ACCESSION NUMBER: 0000899243-21-035417
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210908
FILED AS OF DATE: 20210909
DATE AS OF CHANGE: 20210909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Trigilio Jeffrey
CENTRAL INDEX KEY: 0001838671
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 211244567
MAIL ADDRESS:
STREET 1: C/O CULLINAN MANAGEMENT, INC.
STREET 2: ONE MAIN STREET, SUTIE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-08
0
0001789972
Cullinan Oncology, Inc.
CGEM
0001838671
Trigilio Jeffrey
C/O CULLINAN ONCOLOGY, INC.
ONE MAIN STREET, SUITE 520
CAMBRIDGE
MA
02142
0
1
0
0
Chief Financial Officer
Common Stock
2021-09-08
4
M
0
15000
4.30
A
17250
D
Common Stock
2021-09-08
4
S
0
5487
27.83
D
11763
D
Common Stock
2021-09-08
4
S
0
9513
28.85
D
2250
D
Stock Option (Right to Buy)
4.30
2021-09-08
4
M
0
15000
0.00
D
2030-10-28
Common Stock
15000
237891
D
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.40 to $29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/ Jeffrey Trigilio
2021-09-09